This study is testing a drug called Chiauranib for people with advanced solid tumors, including small cell lung cancer (SCLC), that have come back or are resistant to standard treatments. The main goals are to find out how safe Chiauranib is, what side effects it might cause, and to determine the highest dose that can be given safely (MTD) and the recommended dose for future studies (RP2D). You would take Chiauranib once a day in cycles. The study is open to adults aged 18 and older with various advanced solid tumors. This trial is currently recruiting about 36 participants.

Study design

This is a Phase 1b/2, single-arm, open-label study, meaning all participants receive Chiauranib and everyone knows what treatment is being given. It aims to enroll about 36 participants.

What's involved

Participants will undergo a single-dose period of 6 days, followed by a consecutive-dose period of 28 days. For Phase 2, patients will take Chiauranib once daily for continuous 28-day cycles.

Compensation

Not stated in the trial record.

Follow-up

Safety will be monitored for up to 30 days after you take your last dose of Chiauranib. Dose-limiting toxicities (DLTs) and the recommended dose will be evaluated over 34 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.